Agent Capital
VC Fund
Cambridge, United States
Agent Capital is a VC fund in Cambridge focused on Biotechnology and Health Care. A biotech venture capital firm.
- Total investments:
- 53
- Last investment:
- Lead investor:
- 8%
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Agent Capital invests in
Stages Agent Capital invests in
Countries Agent Capital invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Geeta Vemuri
|
|||
Preston Noon
|
|||
Investment Focus
Industry
- Biotechnology 32 (60%)
- Health Care 22 (42%)
- Therapeutics 17 (32%)
- Medical 10 (19%)
- Life Science 9 (17%)
Stage
- Series B 18 (34%)
- Series A 11 (21%)
- Series C 7 (13%)
- Funding Round 6 (11%)
- Seed 4 (8%)
Country
- United States 33 (62%)
- France 1 (2%)
- Switzerland 1 (2%)
- United Kingdom 1 (2%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Geeta Vemuri
Co-Founder & Managing Partner
|
Co-Founder & Managing Partner | Total investments: 13 | Find email | |
|
Preston Noon
Co-Founder & General Partner
|
Co-Founder & General Partner | Total investments: 1 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
GlycoEra
|
GlycoEra is a CustomGlycan platform that unlocks the power of glycan-mediated biology to develop a pipeline of novel biologics. | $130M / Series B / May 27, 2025 | |
Hone Health
|
Hone treats men's hormone imbalances and low testosterone with at-home lab testing, physician consultations, and medication | $33M / Series A / Jan 28, 2025 | |
Interius BioTherapeutics
|
Interius BioTherapeutics is a biopharmaceutical company that targets cancer. The company spun out the University of Pennsylvania and is targeting cancer. | $21.5M / Jan 01, 2025 | |
TRex Bio
|
TRexBio is a discovery stage biotechnology company leveraging cutting-edge computational biology tools, a focus on human tissue, and expertise in immunobiology to develop revolutionary therapeutics for cancer and inflammatory diseases. Our powerful ‘deep biology’ discovery engine maps human tissue Treg behavior to disease processes, allowing us toidentify and characterize novel targets for therapeutic intervention. Leveraging this platform, we are building a broad portfolio of novel therapies that modulate the immune system to restore human tissue immune homeostasis. | $84M / Series B / Nov 13, 2024 | |
Foresight Diagnostics
|
Foresight Diagnostics develops novel technology created to detect cancers earlier from a simple blood draw. | $33M / Series B / Jul 30, 2024 | |
āshibio
|
āshibio creates treatments for rare bone and connective tissue ailments, potentially preventing symptoms or slowing their course. | $40M / Series A / Jun 20, 2024 | |
Cerevance
|
Cerevance is a biotechnology company that develops novel therapeutics for neurological diseases, including chronic neurodegenerative conditions such as Alzheimer's disease, Parkinson's disease, frontotemporal dementia, and amyotrophic lateral sclerosis. Using a large and growing repository of over 15,000 human brain tissue samples, thecompany generates an unprecedented level of expression and epigenetic data, enabling the company to identify the most promising targets for the next generation of treatments for CNS disorders. | $47M / Series B / Apr 25, 2024 | |
Q32 Bio
|
Q32 Bio is a biotechnology company developing treatments for patients with severe autoimmune and inflammatory diseases. Q32 Bio is addressing dysregulation to help patients take back control of their lives in diseases with few to no treatment options, or those diseases where current therapeutics provide inadequate relief.Q32 Bio consists of ateam of scientists and industry veterans with strong expertise in immunology. The team has a strong track record of discovering and developing new and innovative therapies. | $42M / Mar 25, 2024 | |
|
Q32 Bio
|
Q32 Bio is a biotechnology company developing treatments for patients with severe autoimmune and inflammatory diseases. Q32 Bio is addressing dysregulation to help patients take back control of their lives in diseases with few to no treatment options, or those diseases where current therapeutics provide inadequate relief.Q32 Bio consists of ateam of scientists and industry veterans with strong expertise in immunology. The team has a strong track record of discovering and developing new and innovative therapies. | $42M / Post-IPO Equity / Mar 25, 2024 | |
Cantai Therapeutics
|
Cantai Therapeutics operates as a developer of drug candidates. | $700K / Seed / Nov 20, 2023 | |
| See all 53 investments → | |||
Co-Investors
Penn Medicine Co-Investment Program
8 deals together
Pfizer Venture Investments
8 deals together
Tellus BioVentures
8 deals together
Alexandria Venture Investments
7 deals together
Foresite Capital
7 deals together
Wellington Partners
7 deals together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Agent Capital invest in?
Agent Capital invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Series B and Series A stage. Most of the 53 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Agent Capital?
Public channels for Agent Capital include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Agent Capital?
The team at Agent Capital includes Geeta Vemuri (Co-Founder & Managing Partner) and Preston Noon (Co-Founder & General Partner). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
